Hypoxia- or PDGF-BB-dependent paxillin tyrosine phosphorylation in pulmonary hypertension is reversed by HIF-1α depletion or imatinib treatment

Summary

Chronic exposure to hypoxia induces a pronounced remodelling of the pulmonary vasculature leading to pulmonary hypertension (PH). The remodelling process also entails increased proliferation and decreased apoptosis of pulmonary arterial smooth muscle cells (PASMC), processes regulated by the cytoskeletal protein paxillin. In this study, we aimed to examine the molecular mechanisms leading to deregulation of paxillin in PH. We detected a time-dependent increase in paxillin tyrosine 31 (Y31) and 118 (Y118) phosphorylation following hypoxic exposure (1 % O₂) or platelet-derived growth factor (PDGF)-BB stimulation of primary human PASMC. In addition, both, hypoxia- and PDGF-BB increased the nuclear localisation of phospho-paxillin Y31 as indicated by immunofluorescence staining in human PASMC. Elevated paxillin tyrosine phosphorylation in human PASMC was attenuated by hypoxia-inducible factor (HIF)-1α depletion or by treatment with the PDGF-BB receptor antagonist, imatinib. Moreover, we observed elevated paxillin Y31 and Y118 phosphorylation in the pulmonary vasculature of chronic hypoxic mice (21 days, 10 % O₂) which was reversible by imatinib-treatment. PDGF-BB-dependent PASMC proliferation was regulated via the paxillin-Erk1/2-cyclin D1 pathway. In conclusion, we suggest paxillin up-regulation and phosphorylation as an important mechanism of vascular remodelling underlying pulmonary hypertension.

Note: Parts of the doctoral thesis of Christine Veith are integrated into this report.

Keywords

Pulmonary arterial smooth muscle cells - cytoskeletal proteins - pulmonary hypertension - pulmonary vascular remodelling

• References

• 1 Sylvester JT, Shimoda LA, Aaronson PI. et al. Hypoxic pulmonary vasoconstriction. Physiol Rev 2012; 92: 367-520.
• 2 Stenmark KR, Fagan KA, Frid MG. Hypoxia-induced pulmonary vascular remodeling: cellular and molecular mechanisms. Circ Res 2006; 99: 675-691.
• 3 Hanze J, Weissmann N, Grimminger F. et al. Cellular and molecular mechanisms of hypoxia-inducible factor driven vascular remodeling. Thromb Haemost 2007; 97: 774-787.
• 4 Veith C, Marsh LM, Wygrecka M. et al. Paxillin regulates pulmonary arterial smooth muscle cell function in pulmonary hypertension. Am J Pathol 2012; 181: 1621-1633.
• 5 Veith C, Schmitt S, Veit F. et al. Cofilin, a hypoxia-regulated protein in murine lungs identified by 2DE: role of the cytoskeletal protein cofilin in pulmonary hypertension. Proteomics 2013; 13: 75-88.
• 6 Nagaraj C, Tang B, Balint Z. et al. Src tyrosine kinase is crucial for potassium channel function in human pulmonary arteries. Eur Respir J 2013; 41: 85-95.
• 7 Kwapiszewska G, Wygrecka M, Marsh LM. et al. Fhl-1, a new key protein in pulmonary hypertension. Circulation 2008; 118: 1183-1194.
• 8 Deakin NO, Turner CE. Paxillin comes of age. J Cell Sci 2008; 121: 2435-2444.
• 9 Schwartz MA. Integrins and extracellular matrix in mechanotransduction. Cold Spring Harb Perspect Biol 2010; 02: a005066.
• 10 Vuori K. Integrin signaling: tyrosine phosphorylation events in focal adhesions. J Membr Biol 1998; 165: 191-199.
• 11 Turner CE. Paxillin interactions. J Cell Sci 2000; 113: 4139-4140.
• 12 Bellis SL, Perrotta JA, Curtis MS. et al. Adhesion of fibroblasts to fibronectin stimulates both serine and tyrosine phosphorylation of paxillin. Biochem J 1997; 325: 375-381.
• 13 Burridge K, Turner CE, Romer LH. Tyrosine phosphorylation of paxillin and pp125FAK accompanies cell adhesion to extracellular matrix: a role in cytoskeletal assembly. J Cell Biol 1992; 119: 893-903.
• 14 Petit V, Boyer B, Lentz D. et al. Phosphorylation of tyrosine residues 31 and 118 on paxillin regulates cell migration through an association with CRK in NBT-II cells. J Cell Biol 2000; 148: 957-970.
• 15 Abedi H, Zachary I. Vascular endothelial growth factor stimulates tyrosine phosphorylation and recruitment to new focal adhesions of focal adhesion kinase and paxillin in endothelial cells. J Biol Chem 1997; 272: 15442-15451.
• 16 Sen A, O’Malley K, Wang Z. et al. Paxillin regulates androgen- and epidermal growth factor-induced MAPK signaling and cell proliferation in prostate cancer cells. J Biol Chem 2010; 285: 28787-28795.
• 17 Brown MC, Turner CE. Paxillin: adapting to change. Physiol Rev 2004; 84: 1315-1339.
• 18 Dahal BK, Heuchel R, Pullamsetti SS. et al. Hypoxic pulmonary hypertension in mice with constitutively active platelet-derived growth factor receptor-beta. Pulmonary Circ 2011; 01: 259-268.
• 19 Kwapiszewska G, Wilhelm J, Wolff S. et al. Expression profiling of laser-micro-dissected intrapulmonary arteries in hypoxia-induced pulmonary hypertension. Respir Res 2005; 06: 109.
• 20 Schermuly RT, Dony E, Ghofrani HA. et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 2005; 115: 2811-2821.
• 21 Amagasaki K, Kaneto H, Heldin CH. et al. c-Jun N-terminal kinase is necessary for platelet-derived growth factor-mediated chemotaxis in primary fibroblasts. J Biol Chem 2006; 281: 22173-22179.
• 22 Berrou E, Bryckaert M. Platelet-derived growth factor inhibits smooth muscle cell adhesion to fibronectin by ERK-dependent and ERK-independent pathways. J Biol Chem 2001; 276: 39303-39309.
• 23 Weissmann N, Gerigk B, Kocer O. et al. Hypoxia-induced pulmonary hypertension: different impact of iloprost, sildenafil, and nitric oxide. Respir Med 2007; 101: 2125-2132.
• 24 Veit F, Pak O, Egemnazarov B. et al. Function of NADPH oxidase 1 in pulmonary arterial smooth muscle cells after monocrotaline-induced pulmonary vascular remodeling. Antioxidant Redox Signal 2013; 19: 2213-2231.
• 25 Stenmark KR, Frid MG. Smooth muscle cell heterogeneity: role of specific smooth muscle cell subpopulations in pulmonary vascular disease. Chest 1998; 114 (Suppl. 01) 82S-90S.
• 26 Firth AL, Choi IW, Park WS. Animal models of pulmonary hypertension: Rho kinase inhibition. Prog Biophys Mol Biol 2012; 109: 67-75.
• 27 Schaller MD. Paxillin: a focal adhesion-associated adaptor protein. Oncogene 2001; 20: 6459-6472.
• 28 Azuma K, Tanaka M, Uekita T. et al. Tyrosine phosphorylation of paxillin affects the metastatic potential of human osteosarcoma. Oncogene 2005; 24: 4754-4764.
• 29 Sachdev S, Bu Y, Gelman IH. Paxillin-Y118 phosphorylation contributes to the control of Src-induced anchorage-independent growth by FAK and adhesion. BMC Cancer 2009; 09: 12.
• 30 Dong JM, Lau LS, Ng YW. et al. Paxillin nuclear-cytoplasmic localization is regulated by phosphorylation of the LD4 motif: evidence that nuclear paxillin promotes cell proliferation. Biochem J 2009; 418: 173-184.
• 31 Woods AJ, Kantidakis T, Sabe H. et al. Interaction of paxillin with poly(A)-binding protein 1 and its role in focal adhesion turnover and cell migration. Mol Cell Biol 2005; 25: 3763-3773.
• 32 Woods AJ, Roberts MS, Choudhary J. et al. Paxillin associates with poly(A)-binding protein 1 at the dense endoplasmic reticulum and the leading edge of migrating cells. J Biol Chem 2002; 277: 6428-6437.
• 33 Wang Y, Gilmore TD. Zyxin and paxillin proteins: focal adhesion plaque LIM domain proteins go nuclear. Biochim Biophys Acta 2003; 1593: 115-120.
• 34 Shibanuma M, Kim-Kaneyama JR, Ishino K. et al. Hic-5 communicates between focal adhesions and the nucleus through oxidant-sensitive nuclear export signal. Mol Biol Cell 2003; 14: 1158-1171.
• 35 Sundberg-Smith LJ, DiMichele LA, Sayers RL. et al. The LIM protein leupaxin is enriched in smooth muscle and functions as an serum response factor cofactor to induce smooth muscle cell gene transcription. Circ Res 2008; 102: 1502-1511.
• 36 Kato T, Muraski J, Chen Y. et al. Atrial natriuretic peptide promotes cardiomyocyte survival by cGMP-dependent nuclear accumulation of zyxin and Akt. J Clin Invest 2005; 115: 2716-2730.
• 37 Ghofrani HA, Seeger W, Grimminger F. Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med 2005; 353: 1412-1413.
• 38 Rembold CM, Tejani AD, Ripley ML. et al. Paxillin phosphorylation, actin polymerization, noise temperature, and the sustained phase of swine carotid artery contraction. Am J Physiol Cell Physiol 2007; 293: C993-1002.
• 39 Zhang W, Huang Y, Gunst SJ. The small GTPase RhoA regulates the contraction of smooth muscle tissues by catalyzing the assembly of cytoskeletal signaling complexes at membrane adhesion sites. J Biol Chem 2012; 287: 33996-34008.
• 40 Barman SA, Zhu S, White RE. RhoA/Rho-kinase signaling: a therapeutic target in pulmonary hypertension. Vasc Health Risk Manag 2009; 05: 663-671.
• 41 Ishikura K, Yamada N, Ito M. et al. Beneficial acute effects of rho-kinase inhibitor in patients with pulmonary arterial hypertension. Circ J 2006; 70: 174-178.
• 42 Laumanns IP, Fink L, Wilhelm J. et al. The noncanonical WNT pathway is operative in idiopathic pulmonary arterial hypertension. Am J Respir Cell Mol Biol 2009; 40: 683-691.
• 43 Hagel M, George EL, Kim A. et al. The adaptor protein paxillin is essential for normal development in the mouse and is a critical transducer of fibronectin signaling. Mol Cell Biol 2002; 22: 901-915.